What exhibits related to the Marizyme note are included with this Qualigen 8-K?

The filing lists the Amended and Restated Secured Demand Promissory Note dated August 21, 2025, as Exhibit 10.1 and Amendment No. 1 dated September 15, 2025, as Exhibit 10.2.

Qualigen updates secured Marizyme note terms

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Qualigen Therapeutics, Inc. filed a current report describing an amendment to its secured borrowing arrangement with Marizyme, Inc. On September 15, 2025, the company entered into Amendment No. 1 to its Amended and Restated Secured Demand Promissory Note dated August 21, 2025.

The amendment corrects the note’s maturity date to August 21, 2026, increases the advance and principal amount by $75,000, and results in a revised outstanding principal balance of $4,526,462.18. The additional advance accrues interest at the same rate set in the existing note, and the company’s obligations remain secured under the existing Security Agreement. The amendment also triggers disclosure of a direct financial obligation under the relevant reporting item.

8-K Event Classification

3 items: 1.01, 2.03, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Qualigen Therapeutics (QLGN) disclose in this 8-K filing?

Qualigen Therapeutics reported entering into Amendment No. 1 to its Amended and Restated Secured Demand Promissory Note with Marizyme, Inc., updating the maturity date, principal amount, and confirming the secured status of the obligation.

How did the amendment affect Qualigen Therapeutics’ promissory note with Marizyme?

The amendment increased the advance and principal amount outstanding by $75,000, bringing the revised outstanding principal balance to $4,526,462.18, and confirmed that the additional advance accrues interest at the same rate as in the existing note.

What is the new maturity date of Qualigen’s amended and restated note?

The amendment corrects the maturity date of the Amended and Restated Secured Demand Promissory Note to August 21, 2026.

Does the Marizyme promissory note remain secured after the amendment?

Yes. The amendment reaffirms that Qualigen Therapeutics’ obligations under the note remain secured under the existing Security Agreement.

Which reporting items in the 8-K are associated with this debt amendment?

The amendment is disclosed under Item 1.01 as entry into a material definitive agreement, and Item 2.03 incorporates that information as the creation of a direct financial obligation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 09/16/2025 - 09:46 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2025

Qualigen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-37428

26-3474527

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

5857 Owens Avenue, Suite 300, Carlsbad, California 92008

(Address of principal executive offices) (Zip Code)

(760) 452-8111

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QLGN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 1.01. Entry into a Material Definitive Agreement.

On September 15, 2025, Qualigen Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to the Amended and Restated Secured Demand Promissory Note dated August 21, 2025 (the “Amended and Restated Note”) with Marizyme, Inc. The Amendment corrects the maturity date of the Amended and Restated Note to August 21, 2026, increases the “Advance” and corresponding principal amount outstanding by $75,000, resulting in a revised outstanding principal balance of $4,526,462.18, and provides that the additional advance accrues interest at the rate set forth in the Amended and Restated Note. The Amendment also reaffirms that the Company’s obligations remain secured under the existing Security Agreement. The foregoing description of the Amendment and the transactions contemplated thereby does not purport to be complete and is only a draft summary, and it is qualified in its entirety by reference to Exhibit 10.2, which is incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information contained in Item 1.01 above is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1		Amended and Restated Secured Demand Promissory Note (including Security Agreement), dated August 21, 2025, by and between Marizyme, Inc. and Qualigen Therapeutics, Inc. (incorporated by reference to the Company’s Current Report on Form 8-K filed on August 27, 2025).
10.2		Amendment No. 1 to Amended and Restated Secured Demand Promissory Note, dated September 15, 2025, by and between Marizyme, Inc. and Qualigen Therapeutics, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	QUALIGEN THERAPEUTICS, INC.

Date: September 16, 2025	By:	/s/ Kevin Richardson II
	Name:	Kevin Richardson II
	Title:	Interim Chief Executive Officer

Source: View Original Filing on SEC EDGAR